Prostacyclin Therapy for Pulmonary Arterial Hypertension: New Directions

 

 Buy Article Permissions and Reprints

ABSTRACT

Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and smooth muscle cell proliferation of the pulmonary arterioles, as well as in situ thrombosis of the small pulmonary arteries. Prostacyclin is involved in PAH vascular remodeling. It is unclear if decreased prostacyclin in the lungs is a cause or a consequence of PAH, but the relative lack of prostacyclin and its positive effects on the pulmonary vascular bed support the theory that long-term prostacyclin replacement is effective. Current therapies based on evidence-based medicine include epoprostenol, treprostinil, iloprost, and beraprost, each with limitations based on the drugs' inherent properties and administration route. Treatment of PAH by inhibiting multiple pathways concurrently may produce additive benefit. Because prostacyclin therapy is not curative and does not normalize pulmonary hemodynamics in the majority of cases, combining a prostacyclin with other PAH agents may be a promising approach.

REFERENCES

• 1 Geraci M W, Gao B, Shepherd D C et al.. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension.  J Clin Invest. 1999;  103 1509-1515
  CrossrefPubMedGoogle Scholar
• 2 Nagaya N, Yokoyama C, Kyotani S et al.. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats.  Circulation. 2000;  102 2005-2010
  PubMedGoogle Scholar
• 3 Tuder R, Cool C, Geraci M et al.. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.  Am J Respir Crit Care Med. 1999;  159 1925-1932
  CrossrefPubMedGoogle Scholar
• 4 Zucker T P, Bonisch D, Hasse A, Grosser T, Weber A A, Schror K. Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells.  Eur J Pharmacol. 1998;  345 213-220
  CrossrefPubMedGoogle Scholar
• 5 Christman B, McPherson C, Newman J et al.. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.  N Engl J Med. 1992;  327 70-75
  CrossrefPubMedGoogle Scholar
• 6 Welsh C, Hassell K, Badesch D, Kressin D, Marlar R. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension.  Chest. 1996;  110 710-717
  PubMedGoogle Scholar
• 7 Moncada S, Vane J R. Prostacyclin: homeostatic regulator or biological curiosity?.  Clin Sci (Lond). 1981;  61 369-372
  PubMedGoogle Scholar
• 8 Miyamori I, Morise T, Yasuhara S, Takeda Y, Koshida H, Takeda R. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.  Br J Clin Pharmacol. 1985;  20 681-683
  PubMedGoogle Scholar
• 9 Cheng Y, Austin S C, Rocca B et al.. Role of prostacyclin in the cardiovascular response to thromboxane A2.  Science. 2002;  296 539-541
  CrossrefPubMedGoogle Scholar
• 10 Oudiz R J, Schilz R J, Barst R J et al.. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.  Chest. 2004;  126 420-427
  CrossrefPubMedGoogle Scholar
• 11 McLaughlin V, Genthner D, Panella M, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.  N Engl J Med. 1998;  338 273-277
  CrossrefPubMedGoogle Scholar
• 12 Blumberg F, Riegger G, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise.  Chest. 2002;  121 1566-1571
  CrossrefPubMedGoogle Scholar
• 13 Clapp L, Finney P, Turcato S, Tran S, Rubin L, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.  Am J Respir Cell Mol Biol. 2002;  26 194-201
  PubMedGoogle Scholar
• 14 Data J L, Molony B A, Meinzinger M M, Gorman R R. Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3′:5′-cyclic monophosphate levels.  Circulation. 1981;  64 4-12
  PubMedGoogle Scholar
• 15 Hyman A L, Kadowitz P J. Pulmonary vasodilator activity of prostacyclin (PGI₂) in the cat.  Circ Res. 1979;  45 404-409
  PubMedGoogle Scholar
• 16 Starling M B, Neutze J M, Elliott R L. Control of elevated pulmonary vascular resistance in neonatal swine with prostacyclin (PGI₂).  Prostaglandins Med. 1979;  3 105-117
  CrossrefPubMedGoogle Scholar
• 17 Weir E K, Rubin L J, Ayres S M et al.. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.  Am Rev Respir Dis. 1989;  140 1623-1630
  PubMedGoogle Scholar
• 18 Rubin L J, Groves B M, Reeves J T, Frosolono M, Handel F, Cato A E. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.  Circulation. 1982;  66 334-338
  PubMedGoogle Scholar
• 19 Reeves J T, Groves B M, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension.  Am Rev Respir Dis. 1986;  134 342-346
  PubMedGoogle Scholar
• 20 Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).  Lancet. 1984;  1 1046-1047
  PubMedGoogle Scholar
• 21 Rubin L, Mendoza J, Hood M et al.. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol).  Ann Intern Med. 1990;  112 485-491
  CrossrefPubMedGoogle Scholar
• 22 Nootens M, Schrader B, Kaufman E et al.. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.  Chest. 1995;  107 54
  PubMedGoogle Scholar
• 23 Raffy O, Azarian R, Brenot F et al.. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension.  Circulation. 1996;  93 484
  PubMedGoogle Scholar
• 24 Krasuski R, Warner J, Wang A, Harrison J, Tapson V, Bashore T. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology.  J Am Coll Cardiol. 2000;  36 2204-2211
  CrossrefPubMedGoogle Scholar
• 25 Ricciardi M, Knight B, Martinez F, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine.  J Am Coll Cardiol. 1998;  32 1068-1073
  CrossrefPubMedGoogle Scholar
• 26 Barst R, Rubin L, Long W et al.. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.  N Engl J Med. 1996;  334 296-301
  CrossrefPubMedGoogle Scholar
• 27 Sitbon O, Humbert M, Nunes H et al.. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.  J Am Coll Cardiol. 2002;  40 780-788
  CrossrefPubMedGoogle Scholar
• 28 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.  Circulation. 2002;  106 1477-1482
  CrossrefPubMedGoogle Scholar
• 29 Badesch D, Tapson V, McGoon M et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease.  Ann Intern Med. 2000;  132 425-434
  PubMedGoogle Scholar
• 30 Kuhn K, Byrne D, Arbogast P G et al.. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.  Am J Respir Crit Care Med. 2003;  167 580-586
  CrossrefPubMedGoogle Scholar
• 31 Humbert M, Sanchez O, Fartoukh M et al.. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.  Eur Respir J. 1999;  13 1351-1356
  PubMedGoogle Scholar
• 32 Rosenzweig E, Kerstein D, Barst R. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation. 1999;  99 1858-1865
  CrossrefPubMedGoogle Scholar
• 33 Tan H P, Markowitz J S, Montgomery R A et al.. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol.  Liver Transpl. 2001;  7 745-749
  CrossrefPubMedGoogle Scholar
• 34 Plotkin J S, Kuo P C, Rubin L J et al.. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension.  Transplantation. 1998;  65 457-459
  PubMedGoogle Scholar
• 35 Nunes H, Humbert M, Sitbon O et al.. Prognositc factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2003;  167 1433-1439
  CrossrefPubMedGoogle Scholar
• 36 Aguilar R, Farber H. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.  Am J Respir Crit Care Med. 2000;  162 1846-1850
  PubMedGoogle Scholar
• 36a Robbins I M, Chirstman B W, Newman J H et al.. A survey of diagnostic practices and the use of epoprostenal in patients with primary pulmonary hypertension.  Chest. 1998;  114 1269-1275
  CrossrefPubMedGoogle Scholar
• 37 Rubin L J. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(Suppl 1) 4S-6S
  CrossrefPubMedGoogle Scholar
• 38 Rubin L J. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(Suppl 1) 7S-10S
  CrossrefPubMedGoogle Scholar
• 39 Badesch D B, Abman S H, Ahearn G S et al.. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(Suppl 1) 35S-62S
  CrossrefPubMedGoogle Scholar
• 40 Wade M, Baker F J, Roscigno R, DellaMaestra W, Hunt T L, Lai A A. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.  J Clin Pharmacol. 2004;  44 83-88
  CrossrefPubMedGoogle Scholar
• 41 Simonneau G, Barst R J, Galie N et al.. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
  CrossrefPubMedGoogle Scholar
• 42 Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers.  J Cardiovasc Pharmacol. 2004;  44 209-214
  PubMedGoogle Scholar
• 43 Hoeper M, Schwarze M, Ehlerding S et al.. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.  N Engl J Med. 2000;  342 1866-1870
  CrossrefPubMedGoogle Scholar
• 44 Gessler T, Schmehl T, Hoeper M M et al.. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension.  Eur Respir J. 2001;  17 14-19
  CrossrefPubMedGoogle Scholar
• 45 Olschewski H, Simonneau G, Galie N et al.. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
  CrossrefPubMedGoogle Scholar
• 46 Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease.  Am J Cardiol. 2003;  92 1007-1009
  CrossrefPubMedGoogle Scholar
• 47 Opitz C F, Wensel R, Bettmann M et al.. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation.  Eur Heart J. 2003;  24 356-365
  PubMedGoogle Scholar
• 48 Galie N, Humbert M, Vachiery J-L et al.. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.  J Am Coll Cardiol. 2002;  39 1496-1502
  CrossrefPubMedGoogle Scholar
• 49 Barst R, McGoon M, McLaughlin V et al.. Beraprost therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  41 2119-2125
  CrossrefPubMedGoogle Scholar
• 50 Rubin L, Badesch D, Barst R et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
  CrossrefPubMedGoogle Scholar
• 51 Humbert M, Barst R J, Robbins I M et al.. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.  Eur Respir J. 2004;  24 353-359
  CrossrefPubMedGoogle Scholar
• 52 Hoeper M M, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
  CrossrefPubMedGoogle Scholar
• 53 Itoh T, Nagaya N, Fujii T et al.. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats.  Am J Respir Crit Care Med. 2004;  169 34-38
  PubMedGoogle Scholar
• 54 Ghofrani H A, Rose F, Schermuly R T et al.. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  42 158-164
  CrossrefPubMedGoogle Scholar
• 55 Stiebellehner L, Petkov V, Vonbank K et al.. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.  Chest. 2003;  123 1293-1295
  CrossrefPubMedGoogle Scholar

Mardi Gomberg-MaitlandM.D. M.Sc. 

Division of Cardiology, University of Chicago Hospitals

5841 S. Maryland Ave., MC2016

Chicago, IL 60637

Email: mgomberg@medicine.bsd.uchicago.edu